Brooks, Moore & Associates, Inc. Eli Lilly & CO Transaction History

Brooks, Moore & Associates, Inc.

$168 Million
Q3 2024

A detailed history of Brooks, Moore & Associates, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Brooks, Moore & Associates, Inc. holds 3,368 shares of LLY stock, worth $2.52 Million. This represents 1.77% of its overall portfolio holdings.

Number of Shares

3,368

Previous 3,920 14.08%

Holding current value

$2.52 Million

Previous $3.55 Million 15.95%

% of portfolio

1.77%

Previous 2.29%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$772.14 - $960.02 $426,221 - $529,931	-552 Reduced 14.08%	3,368 $2.98 Million
Q2 2024 Aug 15, 2024	BUY	$724.87 - $909.04 $133,376 - $167,263	184 Added 4.93%	3,920 $3.55 Million
Q1 2024 May 14, 2024	SELL	$592.2 - $792.28 $29,610 - $39,614	-50 Reduced 1.32%	3,736 $2.91 Million
Q4 2023 Feb 15, 2024	SELL	$525.19 - $619.13 $18,906 - $22,288	-36 Reduced 0.94%	3,786 $2.21 Million
Q3 2023 Nov 15, 2023	SELL	$434.7 - $599.3 $325,155 - $448,276	-748 Reduced 16.37%	3,822 $2.05 Million
Q2 2023 Aug 15, 2023	SELL	$350.74 - $468.98 $36,476 - $48,773	-104 Reduced 2.23%	4,570 $2.14 Million
Q1 2023 May 15, 2023	BUY	$310.63 - $364.82 $3,416 - $4,013	11 Added 0.24%	4,674 $1.61 Million
Q4 2022 Feb 03, 2023	SELL	$321.55 - $374.67 $16,399 - $19,108	-51 Reduced 1.08%	4,663 $1.71 Million
Q2 2022 Aug 04, 2022	SELL	$278.73 - $327.27 $197,619 - $232,034	-709 Reduced 13.07%	4,714 $1.53 Million
Q1 2022 May 03, 2022	SELL	$234.69 - $291.66 $58,672 - $72,915	-250 Reduced 4.41%	5,423 $1.55 Million
Q4 2021 Feb 04, 2022	SELL	$224.85 - $279.04 $28,780 - $35,717	-128 Reduced 2.21%	5,673 $1.57 Million
Q3 2021 Nov 08, 2021	SELL	$221.6 - $272.71 $22,160 - $27,270	-100 Reduced 1.69%	5,801 $1.34 Million
Q1 2021 May 04, 2021	BUY	$164.32 - $212.72 $246,480 - $319,080	1,500 Added 34.08%	5,901 $1.1 Million
Q3 2020 Nov 02, 2020	SELL	$146.22 - $169.13 $6,141 - $7,103	-42 Reduced 0.95%	4,401 $651,000
Q2 2020 Aug 10, 2020	BUY	$136.42 - $164.18 $47,474 - $57,134	348 Added 8.5%	4,443 $729,000
Q1 2020 Apr 22, 2020	SELL	$119.05 - $147.35 $68,334 - $84,578	-574 Reduced 12.29%	4,095 $568,000
Q3 2019 Oct 25, 2019	SELL	$106.79 - $116.16 $48,162 - $52,388	-451 Reduced 8.81%	4,669 $522,000
Q2 2019 Aug 09, 2019	SELL	$110.79 - $129.32 $102,591 - $119,750	-926 Reduced 15.32%	5,120 $567,000
Q1 2019 Apr 24, 2019	BUY	$111.31 - $131.02 $14,470 - $17,032	130 Added 2.2%	6,046 $785,000
Q4 2018 Feb 06, 2019	BUY	$105.9 - $118.64 $626,504 - $701,874	5,916 New	5,916 $685,000

Others Institutions Holding LLY

# of Institutions

4,004

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brooks, Moore & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brooks, Moore & Associates, Inc. with notifications on news.

Account

Brooks, Moore & Associates, Inc. Eli Lilly & CO Transaction History